Inventiva S.A. American Depository Shares

Inventiva S.A. is a clinical-stage biopharmaceutical company headquartered in Daix, France, focused on the discovery and development of oral small-molecule therapies for diseases with significant unmet medical needs. The company's lead product candidate, lanifibranor, is a pan-PPAR agonist (PPARα/δ/γ) that has received FDA Breakthrough Therapy Designation and is being evaluated in a global Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH. Beyond MASH, Inventiva is advancing programs in fibrosis-related conditions including systemic sclerosis (SSc) and lysosomal storage disorders. Founded in 2011 and publicly traded on Nasdaq under the ticker IVA, the company leverages its proprietary nuclear receptor expertise and in-house chemistry capabilities to build a diversified pipeline targeting fibrosis and metabolic diseases.